You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Updates in NHL: Expert-Selected Data From the 2022 Summer Hematology Meetings

  • Authors: Ian Flinn, MD, PhD; Kami Maddocks, MD; Steven Treon, MD, PhD
  • CME / ABIM MOC Released: 7/7/2022
  • Valid for credit through: 7/7/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for community-based hematologists/oncologists, cardiologists (including cardio-oncologists), and other healthcare providers (HCPs) involved in the care of patients with lymphomas.

The goal of this activity is that learners will be better able to improve their knowledge of timely data updates and clinical context regarding the management of non-Hodgkin lymphomas (NHLs), from the 2022 summer hematology meetings.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Emerging treatment strategies for NHLs
  • Demonstrate greater confidence in their ability to
    • Apply recent data in the field of NHL to clinical practice


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


  • Ian Flinn, MD, PhD

    Director of Lymphoma Research Program  
    Sarah Cannon Research Institute  
    Tennessee Oncology  
    Nashville, Tennessee


    Ian Flinn, MD, PhD , has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; AstraZeneca; BeiGene; Century Therapeutics; Genentech; Genmab; Gilead Sciences; Great Point Partners; Hutchison MediPharma; Iksuda Therapeutics; InnoCare Pharma; Janssen; Juno Therapeutics; Kite Pharma; MorphoSys; Novartis; Nurix Therapeutics; Pharmacyclics; Roche; Seagen Inc., formerly Seattle Genetics Inc.; Servier Pharmaceuticals; Takeda; TG Therapeutics; Unum Therapeutics; Verastem; Vincerx Pharma; Yingli Pharmaceuticals
    Research funding from: AbbVie; Acerta Pharma; Agios; ArQule; AstraZeneca; BeiGene; Biopath; Bristol Myers Squibb; CALIBR; CALGB; Celgene; Constellation Pharmaceuticals; Curis; CTI Biopharma; Fate Therapeutics; Forma Therapeutics; Forty Seven; Genentech; Gilead Sciences; InnoCare Pharma; IGM Biosciences; Incyte; Infinity Pharmaceuticals; Janssen; Kite Pharma; Loxo; Merck; Millennium Pharmaceuticals; MorphoSys; Myeloid Therapeutics; Novartis; Nurix; Pfizer; Pharmacyclics; Portola Pharmaceuticals; Rhizen Pharmaceuticals; Roche; Seagen Inc., formerly Seattle Genetics, Inc.; Tessa Therapeutics; TCR2 Therapeutics; TG Therapeutics; Trillium Therapeutics; Triphase Research & Development Corp.; Unum Therapeutics; Verastem

  • Kami Maddocks, MD

    Professor of Clinical Internal Medicine 
    Division of Hematology 
    The Ohio State University 
    Columbus, Ohio


    Kami Maddocks, MD, has the following relevant financial relationships:
    Consultant or advisor for: Abbvie; Acerta; ADC Therapeutics; AstraZeneca; Beigene; Bristol Myers Squibb; Genentech; Genmab; Gilead; Incyte; Janssen; Kite; Lilly; Morphosys; Pharmacyclics
    Research funding from: Bristol Myers Squibb; Pfizer; Pharmayclics

  • Steven Treon, MD, PhD

    Harvard Medical School 
    Bing Center for Waldenström's Macroglobulinemia 
    Dana Farber Cancer Institute 
    Boston, Massachusetts 


    Steven Treon, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie, Inc; BeiGene, Inc; Janssen Pharmaceuticals, Inc; Pharmacyclics, Inc.
    Research funding from: AbbVie, Inc.; BeiGene, Inc.; Janssen Pharmaceuticals, Inc.; X4 Pharma


  • Megan Whitney, DMD

    Medical Education Director, Medscape, LLC


    Megan Whitney, DMD, has no relevant financial relationships.

Compliance Reviewer

  • Yaisanet Oyola, MD

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Yaisanet Oyola, MD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Updates in NHL: Expert-Selected Data From the 2022 Summer Hematology Meetings

Authors: Ian Flinn, MD, PhD; Kami Maddocks, MD; Steven Treon, MD, PhDFaculty and Disclosures

CME / ABIM MOC Released: 7/7/2022

Valid for credit through: 7/7/2023


Contents of This CME Activity

All sections of this activity are required for credit.

Follicular Lymphoma

Dr Ian Flinn discusses advances in chemoimmunotherapy for follicular lymphoma, with a look ahead at cellular therapies in development.
Ian Flinn, MD, PhD

Mantle Cell Lymphoma

Dr Kami Maddocks evaluates new data in the frontline setting and emerging approaches to relapsed mantle cell lymphoma.
Kami Maddocks, MD

Waldenström Macroglobulinemia and Marginal Zone Lymphoma

Dr Steven Treon breaks down the key questions about Waldenström and MZL addressed at the summer meetings.
Steven Treon, MD, PhD

Pre Assessment

  • Print